You searched for Antibody candidate - Page 48 of 69

News and Trends 12 Sep 2016

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

…that directly contribute to disease. For example, the lead candidate (ASN100) targets 6 cytotoxins produced by Staphylococcus aureus, a common cause of hospital-acquired infections. ASN100 started being evaluated in a…

September 12, 2016 - 6 minutesmins - By Denise Neves Gameiro

In Depth 31 Jan 2024

New epilepsy drugs: what is in the pipeline?

…a global phase 3 program. Cell therapy candidate for drug-resistant epilepsy Based in South San Francisco, biotech company Neurona Therapeutics is currently developing an allogeneic cell therapy candidate for the…

January 31, 2024 - 6 minutesmins - By Willow Shah-Neville

News and Trends 26 Jan 2023

First patient treated in Atrogi type 2 diabetes clinical study

Atrogi AB, an early-stage Swedish pharma company, has announced that the first patient has been enrolled in a phase 1a/b study. Atrogi’s drug candidate, ATR-258 is a first in class…

January 26, 2023 - 2 minutesmins - By Jim Cornall

In Depth 16 Nov 2023

uniQure: is the gene therapy pioneer en route to becoming a biotech rebuff?

…candidate sees mixed results, uniQure stocks drop In the meantime, uniQure was invested in bringing its Huntington’s disease candidate to the market. AMT-130 consists of an adeno-associated virus serotype 5…

November 16, 2023 - 7 minutesmins - By Roohi Mariam Peter

In Depth 14 Mar 2024

Rett syndrome: advances in gene therapy brings hope

…is done by regulating the gene’s expression on a cell-by-cell basis. The candidate TSHA-102 is designed to mediate levels of MeCP2 proteins in the central nervous system without the risk…

March 14, 2024 - 8 minutesmins - By Roohi Mariam Peter

In Depth 25 Jun 2025

ALS: how close are we to a cure?

…patients, or slow disease progression. Even preclinical treatments such as the gene therapy candidate VY9323 have stumbled, but for different reasons. Massachusetts-based Voyager Therapeutics reported that its SOD1 gene-silencing candidate…

June 25, 2025 - 12 minutesmins - By Roohi Mariam Peter

VC finance stock funds ipo gamma delta t cell lava therapeutics

News and Trends 31 Mar 2021

Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells

…based on immune cells known as gamma delta T cells. The proceeds of the IPO will be used to drive the development of the company’s pipeline of bispecific antibody drugs,…

March 31, 2021 - 5 minutesmins - By Anita Chakraverty

Interview 10 May 2021

The Rollercoaster of Repurposing an Arthritis Drug for Covid-19

…position. Shortly after, the company started a program for Covid-19 based on its rheumatoid arthritis drug candidate. With the help of COO Malin Berthold, who had joined Cyxone in August…

May 10, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin

More News! 23 Jul 2024

First AKT-targeting drug capivasertib to hit the market, could it open the door for more?

…clinical trials? Here are a couple of promising candidates in the AKT inhibitor space: Taiho Pharmaceuticals’ TAS-117 Currently in phase 1 clinical trials and tested in patients with advanced solid…

July 23, 2024 - 7 minutesmins - By Jules Adam

News and Trends 26 Jan 2021

Oxford’s Covid-19 Vaccine Blazes Trail for Oncolytic Virus Firms

…advanced candidate — a liver cancer treatment developed by the French biotech Transgene — was abandoned in phase III in 2019. Why have new oncolytic viruses been slow to reach…

January 26, 2021 - 7 minutesmins - By Jonathan Smith

Startup Scout 23 Jun 2017

This Newly Founded French Biotech is All About Vaccines

This week we visited the biotech hub Lyon, where one of our top biotechs Imaxio has recently founded Osivax to advance the development of its innovative vaccine candidates. Mission: Osivax…

June 23, 2017 - 1 minutemin - By Melanie De Almeida

News and Trends 30 Jun 2017

€40M in Series C for a British Biotech Treating Blindness with Gene Therapy

…advanced is Spark Therapeutics, in the US, which expects FDA approval for its lead candidate in retinal disease this year. A second candidate, SPK-7001, is in Phase I/II for choroidemia,…

June 30, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

New epilepsy drugs: what is in the pipeline?

First patient treated in Atrogi type 2 diabetes clinical study

uniQure: is the gene therapy pioneer en route to becoming a biotech rebuff?

Rett syndrome: advances in gene therapy brings hope

ALS: how close are we to a cure?

Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells

The Rollercoaster of Repurposing an Arthritis Drug for Covid-19

First AKT-targeting drug capivasertib to hit the market, could it open the door for more?

Oxford’s Covid-19 Vaccine Blazes Trail for Oncolytic Virus Firms

This Newly Founded French Biotech is All About Vaccines

€40M in Series C for a British Biotech Treating Blindness with Gene Therapy

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!